EUCTR2007-006656-19-GR进行中（未招募）不适用
INVESTIGATION OF THE EFFICACY OF LAPATINIB MONOTHERAPY AND TEMOZOLOMIDE PLUS LAPATINIB COMBINATION, IN RECURRENT HIGH GRADE GLIOMAS. A PHASE I/II STUDY. - N/A
Hellenic Cooperative Oncology Group0 个研究点开始时间: 2008年1月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent 2. Age ³18 years3. Radiographic evidence of recurrent glioma (Gr IV glioblastoma multiforme or Gr III anaplastic astrocytoma). Patients should have achieved CR, PR or SD with prior treatment with RT/ temozolomide (adjuvant or 1st line setting). Early recurrence patients may be included in the phase I study.4. Measurable disease at screening according to RECIST5. ECOG performance status (PS) 0-26. Adequate haematological function (ANC =1.5 x 109/L, Platelet count =100 x 109/L and Haemoglobin =9 g/dL)7. Adequate liver and renal function (Total bilirubin <1.5 x upper limit of normal, AST, ALT <2.5xULN in pts without liver metastases; <5xULN in pts with liver metastase, serum creatinine =1.25xULN or calculated creatinine clearance =50 mL/min)8. LVEF within institutional normal range9. All patients must have archived tumour tissue available for translational research – In a subset of suitable patients fresh tumour tissue will be obtained at screening by stereotactic biopsy and at week 4 of lapatinib treatment.10. Drugs and several herbal constituents (e.g. bergamontin and glabridin), which are inducers or inhibitors of CYP3A4 must not be taken within 10 days prior to initiation of treatment and are prohibited while the patient is being treated with lapatinib (a detailed list is provided in section 5.7)11. If a patient requires anticoagulant therapy the patient may remain on study but should be monitored carefully.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or lactating women2. Clinically significant non-controlled cardiovascular disease 3. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment4. Prior treatment with EGFR inhibitors will not be allowed5. Known hypersensitivity to drugs chemically related to lapatinib 6. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications7. Treatment with EIAEDs will be excluded, use of valproate will be permitted. 8. Patients will be excluded if unable to swallow tablets.9. Active infection.
研究者
相似试验
未知
1 期
Clinical Evaluation of Lapatinib Administered with Capecitabine in Japanese Patients with ErbB2 Overexpressing Advanced or Metastatic Breast CancerJPRN-jRCT2080220386GlaxoSmithKline K.K.50
进行中（未招募）
不适用
Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpressioPatients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breastMedDRA version: 14.1Level: LLTClassification code 10006174Term: Breast adenocarcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065348Term: Breast adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2008-000528-22-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
招募中
2 期
Clinical study evaluating efficacy of Nilotinib in CML patientsChronic myelogenous leukemiaJPRN-UMIN000002579ara Hospital Kinki University School Of Medicine20
招募中
不适用
A clinical trial to determine the effect of olopatadine on itching in hand eczemaHand eczemaJPRN-UMIN000003326Department of Dermatology Tokyo Medical and Dental University50
招募中
不适用
A pilot study to evaluate the efficacy of lafutidine in patients with paclitaxel-induced peripheral neuropathy.gynecological cancerJPRN-UMIN000011890Fukushima medical University Hospital, School of medicine30